Literature DB >> 27412599

Relative Contributions of Herpes Simplex Virus 1 ICP0 and vhs to Loss of Cellular IFI16 Vary in Different Human Cell Types.

Megan H Orzalli1, Nicole M Broekema1, David M Knipe2.   

Abstract

UNLABELLED: The herpes simplex virus 1 (HSV-1) ICP0 protein is an E3 ubiquitin ligase that promotes the degradation of several host cell proteins. Most studies have found that ICP0 promotes the loss of IFI16 in infected cells, but one study reported that ICP0 was not necessary or sufficient for loss of IFI16 in a tumor-derived cell line. Therefore, in this study, we examined the requirement for ICP0 in promoting the loss of IFI16 in several normal and tumor-derived cell lines. HSV-1 infection resulted in an observable decrease of IFI16 protein levels in normal human foreskin fibroblasts (HFFs), normal oral keratinocytes (NOKs), and HeLa cells but not in U2OS cells. During infection with an ICP0-null virus, we observed a reduced loss of IFI16 in HFFs and NOKs but not in HeLa cells. Ectopic expression of ICP0 from a transfected plasmid was sufficient to promote the loss of IFI16 in HFFs and NOKs. In the absence of ICP0, we observed a delayed reduction of IFI16 protein that correlated with a reduction in the steady-state levels of IFI16 mRNA. In addition, we show that the ICP0-independent loss of IFI16 in HeLa cells is dependent in part on the activity of the viral virion host shutoff (vhs) tegument protein. Together, these results demonstrate that HSV-1 promotes the loss of IFI16 through at least two mechanisms: (i) by ICP0-dependent degradation of IFI16 and (ii) by vhs-dependent turnover of IFI16 mRNA. In addition, this study highlights a potential intrinsic difference between normal and tumor-derived cells for the activities of IFI16 and HSV-1 ICP0. IMPORTANCE: HSV-1 is a ubiquitous virus that establishes a lifetime persistent infection in humans. The relative success of HSV-1 as a pathogen is, in part, dependent on the expression of viral proteins that counteract host intrinsic defense mechanisms and that modulate immune responses during viral infection. In this study, we examined the relative roles of two viral gene products for the ability to promote loss of the antiviral IFI16 DNA sensor. We demonstrate that the viral immediate early ICP0 protein plays a dominant role in the loss of IFI16 in normal, but not tumor-derived, human cell lines. In contrast, viral vhs-mediated loss of IFI16 by mRNA destabilization is revealed to be dominant in tumor-derived cells in which ICP0 is nonfunctional. Together, these results contribute to our understanding of how HSV-1 modulates IFI16 protein levels and highlight cell-type-dependent differences between normal and tumor-derived cells.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27412599      PMCID: PMC5008076          DOI: 10.1128/JVI.00939-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

Review 1.  Herpes simplex virus virion host shutoff protein: immune evasion mediated by a viral RNase?

Authors:  James R Smiley
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

2.  Acetylation modulates cellular distribution and DNA sensing ability of interferon-inducible protein IFI16.

Authors:  Tuo Li; Benjamin A Diner; Jin Chen; Ileana M Cristea
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-12       Impact factor: 11.205

3.  cGAS-mediated stabilization of IFI16 promotes innate signaling during herpes simplex virus infection.

Authors:  Megan H Orzalli; Nicole M Broekema; Benjamin A Diner; Dustin C Hancks; Nels C Elde; Ileana M Cristea; David M Knipe
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

4.  Control of mRNA stability by the virion host shutoff function of herpes simplex virus.

Authors:  A A Oroskar; G S Read
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

5.  Effects of herpes simplex virus on mRNA stability.

Authors:  T Strom; N Frenkel
Journal:  J Virol       Date:  1987-07       Impact factor: 5.103

6.  Kaposi's sarcoma-associated herpesvirus latency in endothelial and B cells activates gamma interferon-inducible protein 16-mediated inflammasomes.

Authors:  Vivek Vikram Singh; Nagaraj Kerur; Virginie Bottero; Sujoy Dutta; Sayan Chakraborty; Mairaj Ahmed Ansari; Nitika Paudel; Leela Chikoti; Bala Chandran
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

7.  The herpes simplex virus regulatory protein ICP27 contributes to the decrease in cellular mRNA levels during infection.

Authors:  M A Hardwicke; R M Sandri-Goldin
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

8.  Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway.

Authors:  Lijun Sun; Jiaxi Wu; Fenghe Du; Xiang Chen; Zhijian J Chen
Journal:  Science       Date:  2012-12-20       Impact factor: 47.728

9.  Constitutive interferon-inducible protein 16-inflammasome activation during Epstein-Barr virus latency I, II, and III in B and epithelial cells.

Authors:  Mairaj Ahmed Ansari; Vivek Vikram Singh; Sujoy Dutta; Mohanan Valiya Veettil; Dipanjan Dutta; Leela Chikoti; Jie Lu; David Everly; Bala Chandran
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

10.  Herpes simplex virus type 1 ICP0 regulates expression of immediate-early, early, and late genes in productively infected cells.

Authors:  W Cai; P A Schaffer
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

View more
  39 in total

Review 1.  Innate Immune Mechanisms and Herpes Simplex Virus Infection and Disease.

Authors:  Evelyn A Kurt-Jones; Megan H Orzalli; David M Knipe
Journal:  Adv Anat Embryol Cell Biol       Date:  2017       Impact factor: 1.231

Review 2.  Evasion of Cytosolic DNA-Stimulated Innate Immune Responses by Herpes Simplex Virus 1.

Authors:  Chunfu Zheng
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

3.  Mechanisms of Host IFI16, PML, and Daxx Protein Restriction of Herpes Simplex Virus 1 Replication.

Authors:  Philipp E Merkl; Megan H Orzalli; David M Knipe
Journal:  J Virol       Date:  2018-04-27       Impact factor: 5.103

4.  Human Cytomegalovirus Tegument Protein pp65 (pUL83) Dampens Type I Interferon Production by Inactivating the DNA Sensor cGAS without Affecting STING.

Authors:  Matteo Biolatti; Valentina Dell'Oste; Sara Pautasso; Francesca Gugliesi; Jens von Einem; Christian Krapp; Martin Roelsgaard Jakobsen; Cinzia Borgogna; Marisa Gariglio; Marco De Andrea; Santo Landolfo
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

5.  Impaired STING Pathway in Human Osteosarcoma U2OS Cells Contributes to the Growth of ICP0-Null Mutant Herpes Simplex Virus.

Authors:  Thibaut Deschamps; Maria Kalamvoki
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

Review 6.  The Role of Viral RNA Degrading Factors in Shutoff of Host Gene Expression.

Authors:  Léa Gaucherand; Marta Maria Gaglia
Journal:  Annu Rev Virol       Date:  2022-06-07       Impact factor: 14.263

7.  The intracellular DNA sensors cGAS and IFI16 do not mediate effective antiviral immune responses to HSV-1 in human microglial cells.

Authors:  Austin M Jeffries; Andrew W Truman; Ian Marriott
Journal:  J Neurovirol       Date:  2020-06-02       Impact factor: 2.643

8.  Herpes Simplex Virus 1 γ134.5 Protein Inhibits STING Activation That Restricts Viral Replication.

Authors:  Shuang Pan; Xing Liu; Yijie Ma; Youjia Cao; Bin He
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

Review 9.  The Race between Host Antiviral Innate Immunity and the Immune Evasion Strategies of Herpes Simplex Virus 1.

Authors:  Huifang Zhu; Chunfu Zheng
Journal:  Microbiol Mol Biol Rev       Date:  2020-09-30       Impact factor: 11.056

Review 10.  Host Innate Immune Response and Viral Immune Evasion During Alphaherpesvirus Infection.

Authors:  Krystal K Lum; Ileana M Cristea
Journal:  Curr Issues Mol Biol       Date:  2021-02-28       Impact factor: 2.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.